What Gyre Therapeutics, Inc. told the SEC could break it.

US-China trade tensions have produced tariffs on PRC imports, and a proposed 100% tariff on imported branded/patented pharmaceuticals (unless building US capacity) could disrupt Gyre's cross-border raw-material sourcing and US ambitions.

“In September 2025, President Trump announced plans to impose 100% tariffs on imported branded or patented pharmaceuticals, unless the importing company is building U.S. manufacturing capacity, although the effective d”

Gyre's results depend on PRC government healthcare and pricing policy — including NHSA centralized (volume-based) drug procurement tenders that pressure prices — so ETUARY's volumes and profitability hinge on succeeding in those tender processes.

“The Company's operating results are subject to risks and uncertainties arising from changes in government healthcare policies and pricing regulations in the PRC.”

Gyre's revenue is highly concentrated in three PRC distributors — Sinopharm (51.7%), China Resources Pharmaceutical (13.3%) and Shanghai Pharmaceuticals (11.6%) — with Sinopharm alone ~53.3% of accounts receivable, so loss of any would be materially adverse.

“For the year ended December 31, 2025, three customers, Sinopharm Group Co., Ltd., China Resources Pharmaceutical Group Ltd, and Shanghai Pharmaceuticals Holding Co., Ltd accounted for approximately 51.7 % , 13.3 % , and 11.6 % of total revenue, respectively.”

All of Gyre's commercial customers are in the PRC and 100% of its lead product ETUARY is manufactured at its Beijing and Cangzhou (Hebei) facilities, concentrating both its market and its production in China.

“Our manufacturing facilities are situated in Beijing and Cangzhou, Hebei province, in the PRC. During the year ended December 31, 2025, 100% of ETUARY® we sold was manufactured at our Beijing and Cangzhou facilities.”